AbbVie Inc. $ABBV Position Boosted by Magnolia Capital Advisors LLC

Magnolia Capital Advisors LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 261.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,999 shares of the company’s stock after acquiring an additional 7,231 shares during the quarter. Magnolia Capital Advisors LLC’s holdings in AbbVie were worth $1,856,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Code Waechter LLC grew its stake in AbbVie by 37.3% during the 2nd quarter. Code Waechter LLC now owns 5,322 shares of the company’s stock valued at $988,000 after acquiring an additional 1,447 shares in the last quarter. Huntington National Bank lifted its holdings in shares of AbbVie by 8.6% during the 2nd quarter. Huntington National Bank now owns 675,008 shares of the company’s stock valued at $125,295,000 after buying an additional 53,577 shares during the last quarter. Transatlantique Private Wealth LLC lifted its holdings in shares of AbbVie by 3.2% during the 2nd quarter. Transatlantique Private Wealth LLC now owns 4,443 shares of the company’s stock valued at $825,000 after buying an additional 138 shares during the last quarter. Optivise Advisory Services LLC lifted its holdings in shares of AbbVie by 6.3% during the 2nd quarter. Optivise Advisory Services LLC now owns 1,516 shares of the company’s stock valued at $281,000 after buying an additional 90 shares during the last quarter. Finally, Next Capital Management LLC lifted its holdings in shares of AbbVie by 19.6% during the 2nd quarter. Next Capital Management LLC now owns 1,877 shares of the company’s stock valued at $348,000 after buying an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on ABBV shares. Piper Sandler increased their target price on shares of AbbVie from $231.00 to $284.00 and gave the stock an “overweight” rating in a research report on Friday, October 10th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday. Hsbc Global Res cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $237.85.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $212.04 on Tuesday. The business has a fifty day simple moving average of $222.51 and a 200 day simple moving average of $201.42. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. The firm has a market capitalization of $374.58 billion, a price-to-earnings ratio of 100.97, a PEG ratio of 1.42 and a beta of 0.51. AbbVie Inc. has a one year low of $163.81 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Insider Activity at AbbVie

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.25% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.